These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12425862)

  • 1. Methodologic shortcomings inherent in a post-hoc analysis.
    Staskin DR
    Curr Urol Rep; 2002 Dec; 3(6):431-3. PubMed ID: 12425862
    [No Abstract]   [Full Text] [Related]  

  • 2. POEMS (patient-oriented evidence that matters) spark discussion.
    Weiss BD
    J Fam Pract; 2001 Oct; 50(10):901. PubMed ID: 11674898
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
    Reinberg Y; Crocker J; Wolpert J; Vandersteen D
    J Urol; 2003 Jan; 169(1):317-9. PubMed ID: 12478180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detrol LA and Diropan XL for overactive bladder.
    Med Lett Drugs Ther; 2001 Apr; 43(1101):28. PubMed ID: 11283473
    [No Abstract]   [Full Text] [Related]  

  • 5. RE: Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence.
    Ellsworth P
    J Urol; 2003 Sep; 170(3):928; author reply 928. PubMed ID: 12913741
    [No Abstract]   [Full Text] [Related]  

  • 6. Overactive bladder: improving the efficacy of anticholinergics by dose escalation.
    MacDiarmid SA
    Curr Urol Rep; 2003 Dec; 4(6):446-51. PubMed ID: 14622497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial.
    Appell RA
    Curr Urol Rep; 2002 Oct; 3(5):343-4. PubMed ID: 12354340
    [No Abstract]   [Full Text] [Related]  

  • 8. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
    Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
    Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy of the overactive bladder and advances in drug delivery.
    Cannon TW; Chancellor MB
    Clin Obstet Gynecol; 2002 Mar; 45(1):205-17. PubMed ID: 11862073
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolterodine.
    Hills CJ; Winter SA; Balfour JA
    Drugs; 1998 Jun; 55(6):813-20; discussion 821-2. PubMed ID: 9617596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder.
    Leung HY; Yip SK; Cheon C; Liu YS; Lau J; Wong HK; Chung KH
    BJU Int; 2002 Sep; 90(4):375-80. PubMed ID: 12175392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxybutynin transdermal (Oxytrol) for overactive bladder.
    Med Lett Drugs Ther; 2003 May; 45(1156):38-9. PubMed ID: 12736598
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women.
    Sand PK; Miklos J; Ritter H; Appell R
    Int Urogynecol J Pelvic Floor Dysfunct; 2004; 15(4):243-8. PubMed ID: 15517668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic treatment for detrusor overactivity.
    Lai HH; Boone TB; Appell RA
    Curr Urol Rep; 2002 Oct; 3(5):365-72. PubMed ID: 12354344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The newer antimuscarinic drugs: bladder control with less dry mouth.
    Appell RA
    Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder.
    Getsios D; Caro JJ; Ishak KJ; El-Hadi W; Payne K
    Clin Ther; 2004 Mar; 26(3):431-8. PubMed ID: 15110136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatrics: combining antimuscarinics shows promise for overactive bladder.
    Wyndaele JJ
    Nat Rev Urol; 2010 Feb; 7(2):66-8. PubMed ID: 20145662
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical experiences with tolterodine.
    Nilvebrant L
    Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.